Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer

doi:10.5306/wjco.v6.i5.156

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7897)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

425

WORD

240

HTML

3826

Figures (1-2)

224

Tables (1-4)

251

Sum=4966

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1038

Download

1893

Sum=2931

Oct 10, 2015 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Clin Oncol. Oct 10, 2015; 6(5): 156-165
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.156

Table 4 Myelosuppression rates from prospective trials evaluating concurrent chemoradiation in inoperable non-small cell lung cancer

Ref.	Year	Design	No. of patients	Chemo	Grade 3-4
Ref.	Year	Design	No. of patients	Chemo	Anemia	Leukopenia	Neutropenia
Belani et al[4]	2005	CCRT → Cons	92	Cbp/Pac	10%	51%	26%
Vokes et al[2]	2007	CCRT	184	Cbp/Pac	5%	36%	15%
Hoang et al[5]	2012	CCRT	275	Cbp/Pac	3%	23%	51%
Blumenschein et al[23]	2011	CCRT	87	Cbp/Pac/Cet	“Blood/bone marrow”: 48%

Cbp: Carbo; Pac: Paclitaxel; Cet: Cetuximab; CCRT: Concurrent chemoradiotherpy; Cons: Consolidation.

Citation: Mix M, Ramnath N, Gomez J, Groot C, Rajan S, Dibaj S, Tan W, Rustum Y, Jameson MB, Singh AK. Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer. World J Clin Oncol 2015; 6(5): 156-165
URL: https://www.wjgnet.com/2218-4333/full/v6/i5/156.htm
DOI: https://dx.doi.org/10.5306/wjco.v6.i5.156